The Refractory Angina market growth is driven by factors like increase in the prevalence of Refractory Angina, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Refractory Angina market report also offers comprehensive insights into the Refractory Angina market size, share, Refractory Angina epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Refractory Angina market size growth forward.
Some of the key highlights from the Refractory Angina Market Insights Report:
Strategise your business goals by understanding market dynamics @ Refractory Angina Market Landscape
Refractory Angina Overview
Refractory Angina is conventionally defined as a chronic condition (≥3 months in duration) characterised by angina in the setting of coronary artery disease (CAD), which cannot be controlled by a combination of optimal medical therapy, angioplasty or bypass surgery, and where reversible myocardial ischaemia has been clinically established to be the cause of the symptoms. There is a sensation of pressure or pain in the chest that is the result of insufficient blood flow to the heart muscle and in which treatment with medication and heart surgery is either insufficient or no longer effective. Patients have reproducible lifestyle-limiting symptoms of chest pain, shortness of breath, and easy fatigability. These symptoms are often due to totally occluded coronary arteries or diffuse coronary atherosclerosis that makes revascularization problematic.
Do you know the treatment paradigms for different countries? Download our Refractory Angina Market Sample Report
Refractory Angina Epidemiology Segmentation
DelveInsight’s Refractory Angina market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Refractory Angina historical patient pools and forecasted Refractory Angina patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Refractory Angina Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Visit for more @ Refractory Angina Epidemiological Insights
Refractory Angina Treatment Market
The Refractory Angina market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Refractory Angina market trends by analyzing the impact of current Refractory Angina therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Refractory Angina market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Refractory Angina market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Refractory Angina market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Refractory Angina Emerging Therapies and Key Companies:
Refractory Angina Emerging Drugs
XC001: XyloCor Therapeutics
XC001 is an investigational gene therapy for the treatment of patients with refractory angina with no treatment options. Patients who have exhausted pharmacologic options and are not eligible for PCI or coronary artery bypass grafts become sedentary because of their symptoms and this can exacerbate comorbidities causing rapid deterioration of their health status and results in a poor quality of life because of the associated chest pain caused by the ischemia when even moderate physical exertion occurs. XC001 is designed to stimulate the formation of new coronary blood vessels to serve areas of the heart that are not receiving adequate blood supply. This treatment strategy is based on both pre-clinical and clinical evidence and should enable the patients to become less limited in their daily activities because of debilitating chest pain. An Investigational New Drug (IND) application for XC001 is open with the FDA. XyloCor commenced this Phase 1/2 trial in refractory angina in early 2020.
IMB-101: Imbria pharmaceticals
IMB-101 is a novel, investigational cardiac mitotrope in development for the treatment of cardiovascular disease. As a partial fatty acid oxidation (pFOX) inhibitor, IMB-101 is designed to shift myocardial substrate utilization in favor of glucose oxidation to generate more ATP per unit of oxygen consumed thereby increasing myocardial metabolic efficiency. Currently, it is in phase II stage of development to treat refractory angina.
For more information, visit Refractory Angina Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Refractory Angina Market Report:
Key Questions Answered in the Refractory Angina Market Report 2032:
Table of Contents:
1 Refractory Angina Market Key Comprehensive Insights
2 Refractory Angina Market Report Introduction
3 Competitive Intelligence Analysis for Refractory Angina
4 Refractory Angina Market Analysis Overview at a Glance
5 Executive Summary of Refractory Angina
6 Refractory Angina Epidemiology and Market Methodology
7 Refractory Angina Epidemiology and Patient Population
8 Refractory Angina Patient Journey
9 Refractory Angina Treatment Algorithm, Refractory Angina Current Treatment, and Medical Practices
10 Key Endpoints in Refractory Angina Clinical Trials
11 Refractory Angina Marketed Therapies
12 Refractory Angina Emerging Therapies
13 Refractory Angina: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Refractory Angina
16 Refractory Angina Market Key Opinion Leaders Reviews
18 Refractory Angina Market Drivers
19 Refractory Angina Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Refractory Angina Epidemiology 2032
DelveInsight’s “Refractory Angina – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Refractory Angina epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Refractory Angina Pipeline 2023
“Refractory Angina Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Refractory Angina market. A detailed picture of the Refractory Angina pipeline landscape is provided, which includes the disease overview and Refractory Angina treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/